James William Rogers Sells 1,468 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 1,468 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $40.23, for a total value of $59,057.64. Following the sale, the chief financial officer now owns 229,812 shares in the company, valued at $9,245,336.76. The trade was a 0.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

James William Rogers also recently made the following trade(s):

• On Wednesday, December 11th, James William Rogers sold 83,025 shares of Tempus AI stock. The shares were sold at an average price of $42.30, for a total value of $3,511,957.50.

Tempus AI Stock Down 3.7 %

Shares of NASDAQ:TEM opened at $33.03 on Friday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The company’s 50-day moving average price is $51.96. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $79.49.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TEM. First Horizon Advisors Inc. bought a new stake in shares of Tempus AI in the 3rd quarter worth approximately $30,000. Sandia Investment Management LP bought a new position in shares of Tempus AI during the second quarter valued at approximately $136,000. Vestor Capital LLC purchased a new stake in Tempus AI in the third quarter worth $153,000. Stifel Financial Corp bought a new stake in Tempus AI in the third quarter valued at $218,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in Tempus AI in the third quarter valued at $258,000. Institutional investors own 24.22% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on TEM shares. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and upped their target price for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Bank of America upped their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Wolfe Research started coverage on shares of Tempus AI in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price on the stock. Piper Sandler reissued a “neutral” rating and issued a $70.00 price target (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Finally, Loop Capital raised their price objective on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $56.00.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.